Highlight
1. Among patients with moderate aortic stenosis (AS) and at-risk features, transcatheter aortic valve replacement (TAVR) significantly lowers the composite outcome of death or heart-failure events at 2 years versus clinical surveillance.
2. The PROGRESS randomized trial enrolled 744 patients, revealing a 7.2 percentage point absolute risk reduction in the primary composite endpoint favoring TAVR.
3. Although mortality rates alone were similar, TAVR markedly reduced heart failure events, highlighting its role in mitigating disease progression.
4. Procedural safety was comparable with no meaningful increase in adverse events, supporting TAVR’s feasibility in moderate AS patients at risk.
Study Background
Specialty calculators
For clinical reference; use professional judgment.
